A study of safety, feasibility and immunologic response of transfering tumor infiltrating lymphocytes with or without dendritic cell vaccination in patients with metastatic melanoma

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519060-40-00

Acronym

MAT02

Enrollment

Registered

2025-01-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced metastatic malignant melanoma stage 3 or 4 with measurable lesions in internal organs.

None listed

Sex/Gender

All

Age

18 Years to No maximum

Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026